MCID: BLD039
MIFTS: 34

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 14 69
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 51

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 46 C39836 C4032
SNOMED-CT 64 255110003
UMLS 69 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to colorectal adenocarcinoma and bladder signet ring cell adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways is Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and colon.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 colorectal adenocarcinoma 28.7 CDX2 KRT20 KRT7
2 bladder signet ring cell adenocarcinoma 11.3
3 pelvic lipomatosis 11.1
4 bladder clear cell adenocarcinoma 11.0
5 adenocarcinoma 10.4
6 squamous cell carcinoma of the larynx 10.3 MKI67 PCNA
7 oral leukoplakia 10.3 MKI67 PCNA
8 benign meningioma 10.3 MKI67 PCNA
9 leukoplakia 10.2 MKI67 PCNA
10 prostatic hypertrophy 10.2 KLK3 PCNA
11 salivary gland adenoid cystic carcinoma 10.2 MKI67 PCNA
12 mucinous adenofibroma 10.1 CDX2 KRT7
13 prostate squamous cell carcinoma 10.1 KLK3 KRT7
14 anal canal adenocarcinoma 10.1 CDX2 KRT7
15 epithelial predominant wilms' tumor 10.1 CDX2 KRT7
16 necrotizing sialometaplasia 10.1 KRT7 MKI67
17 bronchiolo-alveolar adenocarcinoma 10.1 CDX2 KRT7
18 nephrogenic adenoma 10.1 KLK3 KRT7
19 nasal cavity adenocarcinoma 10.1 CDX2 KRT7
20 mucinous ovarian cystadenoma 10.1 CDX2 KRT7
21 seminal vesicle tumor 10.1 KLK3 KRT7
22 urethral diverticulum 10.1 KLK3 KRT7
23 endodermal sinus tumor 10.0 KLK3 KRT7
24 duodenum cancer 10.0 CDX2 KRT7
25 anus cancer 10.0 CDX2 KRT7
26 gastric tubular adenocarcinoma 10.0 CDX2 KRT7
27 biliary tract neoplasm 10.0 CDX2 KRT7
28 gastrointestinal system benign neoplasm 10.0 CDX2 KRT7
29 craniopharyngioma 10.0 KRT7 MKI67
30 cavernous hemangioma 10.0 KRT20 MKI67
31 endometrial adenocarcinoma 9.9 KRT7 MKI67
32 prostatic acinar adenocarcinoma 9.9 KLK3 KRT20
33 rete testis adenocarcinoma 9.9 KLK3 KRT20
34 rete testis neoplasm 9.9 KLK3 KRT20
35 cystic basal cell carcinoma 9.9 KRT20 KRT7
36 lung acinar adenocarcinoma 9.9 KRT20 KRT7
37 transverse colon cancer 9.9 KRT20 KRT7
38 actinic keratosis 9.9 KRT20 PCNA
39 ovarian large-cell neuroendocrine carcinoma 9.9 KRT20 KRT7
40 eyelid neoplasm 9.9 KRT20 KRT7
41 malignant syringoma 9.9 KRT20 KRT7
42 krukenberg carcinoma 9.9 KRT20 KRT7
43 bowen's disease 9.9 KRT7 MKI67 PCNA
44 large intestine adenocarcinoma 9.9 KRT20 KRT7
45 linitis plastica 9.9 KRT20 KRT7
46 small cell carcinoma of the bladder 9.9 KRT20 KRT7
47 adenoid squamous cell carcinoma 9.9 KRT20 KRT7
48 eccrine sweat gland neoplasm 9.9 KRT20 KRT7
49 vulval paget's disease 9.9 KRT20 KRT7
50 bile duct cystadenocarcinoma 9.9 KRT20 KRT7

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 Adjuvants, Immunologic Phase 3
5 Alkylating Agents Phase 3,Phase 2
6 Anti-Bacterial Agents Phase 3
7 Antibiotics, Antitubercular Phase 3
8 Anti-Infective Agents Phase 3,Phase 2,Phase 1
9 Antiviral Agents Phase 3,Phase 2
10 Interferon-alpha Phase 3
11 interferons Phase 3
12 Mitomycins Phase 3
13 Nucleic Acid Synthesis Inhibitors Phase 3
14 Pharmaceutical Solutions Phase 3
15 Topoisomerase Inhibitors Phase 3,Phase 2
16 Vaccines Phase 3,Phase 1
17 Antimetabolites Phase 3,Phase 2
18 Antimetabolites, Antineoplastic Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
21
Ifosfamide Approved Phase 2 3778-73-2 3690
22
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
nivolumab Approved Phase 2,Phase 1 946414-94-4
25
Gemcitabine Approved Phase 2 95058-81-4 60750
26
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
27
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
30
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
31
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
32 Piritrexim Investigational Phase 2 72732-56-0
33
Camptothecin Experimental Phase 2 7689-03-4
34 Folic Acid Antagonists Phase 2
35 Vitamin B Complex Phase 2
36 Rubitecan Phase 2
37 topoisomerase I inhibitors Phase 2
38 Albumin-Bound Paclitaxel Phase 2
39 Antimitotic Agents Phase 2
40 Antineoplastic Agents, Phytogenic Phase 2
41 Isophosphamide mustard Phase 2 0
42 Antibodies Phase 2,Phase 1
43 Antibodies, Monoclonal Phase 2,Phase 1
44 Immunoglobulins Phase 2,Phase 1
45 Micronutrients Phase 2
46 Nicotinic Acids Phase 2
47 Protein Kinase Inhibitors Phase 2
48 Trace Elements Phase 2
49 Vitamins Phase 2
50 Folate Nutraceutical Phase 2

Interventional clinical trials:

(show all 17)

# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
5 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
6 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
7 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
8 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
9 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
10 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
11 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
12 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
13 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
14 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
15 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
16 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
17 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

38
Liver, Lung, Colon

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(show all 35)
# Title Authors Year
1
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. ( 28511402 )
2017
2
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. ( 28548125 )
2017
3
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. ( 27006847 )
2016
4
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. ( 27427223 )
2016
5
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. ( 27288750 )
2016
6
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. ( 26955660 )
2016
7
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. ( 27048257 )
2016
8
Gall bladder Adenocarcinoma in a Young Girl. ( 26139973 )
2015
9
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. ( 26421206 )
2015
10
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. ( 24716732 )
2014
11
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. ( 25040620 )
2014
12
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. ( 23589601 )
2013
13
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. ( 24596525 )
2013
14
Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. ( 24281125 )
2013
15
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. ( 23121893 )
2012
16
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. ( 22804747 )
2012
17
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. ( 23076693 )
2012
18
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. ( 22294067 )
2011
19
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. ( 22081531 )
2011
20
Bladder adenocarcinoma following gastrocystoplasty. ( 20392671 )
2010
21
Association of bladder adenocarcinoma and BK virus infection in a pancreatico-renal transplant recipient. ( 28657060 )
2010
22
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. ( 19221283 )
2009
23
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. ( 18307003 )
2008
24
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. ( 18604226 )
2008
25
Urinary bladder adenocarcinoma arising in a spina bifida patient. ( 18022132 )
2007
26
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. ( 15822823 )
2005
27
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. ( 19861819 )
2003
28
Spontaneous resolution of bladder adenocarcinoma. ( 15160537 )
2003
29
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. ( 11506474 )
2001
30
Bladder adenocarcinoma: 31 reported cases. ( 11718635 )
2001
31
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. ( 10510893 )
1999
32
Urine cytology of primary and secondary urinary bladder adenocarcinoma. ( 9915134 )
1998
33
Bladder adenocarcinoma during pregnancy: a case report. ( 8855078 )
1996
34
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. ( 8389497 )
1993
35
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). ( 6983292 )
1982

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

Pathways related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.49 MKI67 PCNA

GO Terms for Bladder Adenocarcinoma

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....